June 26, 2019 Bayer Supervisory Board takes action to address the glyphosate litigation and welcomes the appointment of Ken Feinberg as mediator Read more
SPECIALIZED PRESS June 26, 2019 Not intended for U.S. and UK MediaBayer will present new data on its hemophilia treatments at ISTH 2019Read more
SPECIALIZED PRESS June 26, 2019 Advocate® Spot-on receives positive CVMP opinion for new indicationsAddition of three new therapeutic indications to the Advocate® product information for cats ...Read more
June 24, 2019 Helping growers worldwide to control major pests:Bayer and AlphaBio Control sign distribution agreement for innovative biological pest control productRead more
SPECIALIZED PRESS June 21, 2019 Not intended for U.S. and UK MediaBayer initiates Phase III trial of Aflibercept to prevent blindness in premature infantsRead more
SPECIALIZED PRESS June 19, 2019 Not intended for U.S. and UK MediaRegorafenib to be tested in brain cancer patients in multi-arm cooperation trialGBM AGILE, an international platform trial sponsored by the Global Coalition for Adaptive Research (GCAR) to evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma, is now open for enrollment in the US with regorafenib as the first treatment arm ...Read more
June 14, 2019 Bayer raises the bar in transparency, sustainability and engagementWith its solutions, the company aims to reduce environmental impact by 30 percent / Approximately 5 billion euros will be invested in additional methods to combat weeds over the next decade ...Read more
June 5, 2019 Bayer at the ISF World Seed Congress 2019 in Nice, France:Shaping agriculture through new seed varieties and innovative seed-applied technologiesInnovation and technologies make agriculture more productive and sustainable ...Read more
June 4, 2019 Bayer and Arvinas, Inc. to develop novel Proteolysis-Targeting Chimera candidates for humans and plantsAgreement worth more than USD 110 million includes the first-ever research application of Proteolysis-Targeting Chimera (PROTAC®) technology in agriculture ...Read more
SPECIALIZED PRESS June 3, 2019 Not intended for U.S. and UK Media - Annual Meeting of the American Society of Clinical Oncology (ASCO) 2019:New data on larotrectinib efficacy in patients with TRK fusion cancer and primary CNS tumors or brain metastases presented at ASCO 2019In five TRK fusion cancer patients with brain metastases across different tumor histologies, the overall response rate was 60%, with disease control achieved in all patients ...Read more
.jpg)
